Roche Diagnostics has invested 3.5 billion in China for Expansion of Production Base and R&D Center

On July 9th, Roche Diagnostics Asia-Pacific production base and R&D center built another new manufacturing building-System Reagent Manufacturing Base. It was officially completed in Suzhou Industrial Park. The total investment in the project is 390 million yuan. In the future, the system reagent products manufactured by it will be applied to the modular instruments and pathology laboratory instruments of Roche Diagnostics' central laboratories in China and other countries in the Asia-Pacific region.

Up to now, the total investment of Roche Diagnostics Asia Pacific production base and R&D center has reached 3.5 billion yuan.

In addition, the commercial production of PCR (polymerase chain reaction) medium products invested and constructed by Roche Diagnostics Asia Pacific production base and R&D center was also officially launched on July 9.

Ma Kai, general manager of Roche Diagnostics Asia Pacific production base and R&D center

Ma Kai, general manager of Roche Diagnostics Asia-Pacific production base and R&D center, emphasized: "China is one of Roche Group's global strategic priorities. Roche has always supported the development of China's medical industry, bringing innovative and accurate testing products to Chinese patients, and contributing to a'healthy China'. Contribute to the construction of the country."

Yao Guoliang, General Manager of Roche Diagnostics China

Yao Guoliang, General Manager of Roche Diagnostics China, said: "In the future, Roche Diagnostics will also continue to explore the possibility of more projects landing in China, and work with all parties to promote the realization of medical innovation projects, in order to bring more cutting-edge in vitro diagnostic solutions into China will benefit patients in China and even the Asia-Pacific region."